APHEXDA (Motixafortide Acetate) Patent Expiration, LOE Window & CMS Spending

APHEXDA (Motixafortide Acetate) by Ayrmid: FDA Orange Book core substance LOE 2041-12-29, 0 AB generics, $0 2024 CMS Part D & Medicaid spend, and $5,900 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAyrmid
FDA Application & PathwayN217159 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2041-12-29
Last Listed Patent or Exclusivity Date2041-12-29
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$0
2024 Medicare Part D Spend$0
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($5,900 intro WAC)